SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY 2005 Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309: 99109.
  • 2
    Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE 2004 Adiponectin and its receptors are expressed in bone-forming cells. Bone 35: 842849.
  • 3
    Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I 2005 Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 331: 520526.
  • 4
    Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW 2003 Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33: 646651.
  • 5
    Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 2674626749.
  • 6
    Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K 1996 cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221: 286289.
  • 7
    Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M 1996 Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120: 803812.
  • 8
    Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762769.
  • 9
    Jurimae J, Rembel K, Jurimae T, Rehand M 2005 Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37: 297302.
  • 10
    Hofbauer LC, Heufelder AE 2001 Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79: 243253.
  • 11
    Khosla S 2001 Minireview: The OPG/RANKL/RANK system. Endocrinology 142: 50505055.
  • 12
    Aubin JE, Bonnelye E 2000 Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11: 905913.
  • 13
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345357.
  • 14
    Takahashi N, Udagawa N, Suda T 1999 A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256: 449455.
  • 15
    Robey PG, Termine JD 1985 Human bone cells in vitro. Calcif Tissue Int 37: 453460.
  • 16
    Liao EY, Luo XH 2001 Effects of 17beta-estradiol on the expression of matrix metalloproteinase-1, −2 and tissue inhibitor of metalloproteinase-1 in human osteoblast-like cell cultures. Endocrine 15: 291295.
  • 17
    Luo XH, Liao EY, Su X 2002 Progesterone upregulates TGF-b isoforms (b1, b2, and b3) expression in normal human osteoblast-like cells. Calcif Tissue Int 71: 329334.
  • 18
    Nicholson GC, Malakellis M, Collier FM, Cameron PU, Holloway WR, Gough TJ, Gregorio-King C, Kirkland MA, Myers DE 2000 Induction of osteoclasts from CD14+ human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Colch) 99: 133140.
  • 19
    Itonaga I, Sabokbar A, Sun SG, Kudo O, Danks L, Ferguson D, Fujikawa Y, Athanasou NA 2004 Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 34: 5764.
  • 20
    Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, Gough TJ, Collier GR, Nicholson GC 2002 Leptin inhibits osteoclast generation. J Bone Miner Res 17: 200209.
  • 21
    Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP 2003 Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88: 11011104.
  • 22
    Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G 2003 Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: Comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177: 423433.
  • 23
    Liao EY, Luo XH, Su X 2002 Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest 25: 785790.
  • 24
    Nakayamada S, Okada Y, Saito K, Tamura M, Tanaka Y 2003 Beta1 integrin/focal adhesion kinase-mediated signaling induces intercellular adhesion molecule 1 and receptor activator of nuclear factor kappaB ligand on osteoblasts and osteoclast maturation. J Biol Chem 278: 4536845374.
  • 25
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315323.
  • 26
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 12601268.
  • 27
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610615.
  • 28
    Johnson GL, Vaillancourt RR 1994 Sequential protein kinase reactions controlling cell growth and differentiation. Curr Opin Cell Biol 6: 230238.
  • 29
    Seger R, Krebs EG 1995 The MAPK signaling cascade. FASEB J 9: 726735.
  • 30
    Zhang W, Liu HT 2002 MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 918.
  • 31
    Franceschi RT, Xiao G 2003 Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J Cell Biochem 88: 446454.
  • 32
    Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC 2002 Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282: 117.
  • 33
    Ishida A, Fujita N, Kitazawa R, Tsuruo T 2002 Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J Biol Chem 277: 2621726224.
  • 34
    Kusumi A, Sakaki H, Kusumi Y, Oda M, Narita K, Nakagawa H, Kubota K, Satoh H, Kimura H 2005 Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. J Bone Miner Metab 23: 373381.
  • 35
    Li F, Chung H, Reddy SV, Lu G, Kurihara N, Zhao AZ, Roodman GD 2005 Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res 20: 11611167.
  • 36
    Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, Ikeda T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H 2006 Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem (in press).